India allows Serum Institute to enrol 7-11 year olds in COVID-19 vaccine trial

Reuters
Bengaluru Published: Sep 28, 2021, 02:28 PM(IST)

(File photo) Employees operate a filling machine inside a lab at the Serum Institute of India, in Pune Photograph:( PTI )

Story highlights

Serum Institute is already conducting a trial of its COVID-19 vaccine, a domestically produced version of US drugmaker Novavax`s shot, in the 12-17 age group

India`s drug regulator on Tuesday allowed vaccine maker Serum Institute to enrol kids aged 7-11 years for its COVID-19 vaccine trial as the country prepares to protect children from the coronavirus.

It has already administered more than 870 million doses to adults among its population of nearly 1.4 billion.

Also read | India records 18,795 fresh COVID-19 cases, lowest in six months

"After detailed deliberation, the committee recommended for allowing enrolment of subjects of 7 to 11 years of age group as per the protocol," a subject expert panel of the Central Drugs Standard Control Organization said.

Also read | Covid virus expected to continue to transmit for a very long time, says WHO official

Serum Institute is already conducting a trial of its COVID-19 vaccine, a domestically produced version of US drugmaker Novavax`s shot, in the 12-17 age group and has presented safety data for an initial 100 participants.

So far, only drugmaker Zydus Cadila`s DNA COVID-19 vaccine has received emergency use approval in India to be used in adults and children aged 12 years and above.

Read in App